TNF-α is a pleiotropic cytokine, which plays a major role in the pathogenesis of numerous autoimmune and/or inflammatory systemic diseases. Systemic vasculitis constitutes a group of rare diseases, characterized by inflammation of the arterial or venous vessel wall, causing stenosis and thrombosis. Treatment of the different type of vasculitis mainly relies on steroids and immunosuppressive drugs. In case of refractory or relapsing diseases, however, a second line of treatment may be required. Anti-TNF-α drugs have been used in this setting during the last 15 years with inconsistent results. We reviewed herein the use of anti-TNF-α therapy in different kind of vasculitis and concluded that, except for Behcet's disease, this therapeutic option has not demonstrated significant improvement in the treatment of vasculitis. © 2014 Pierre-André Jarrot and Gilles Kaplanski.
CITATION STYLE
Jarrot, P. A., & Kaplanski, G. (2014). Anti-TNF-alpha therapy and systemic vasculitis. Mediators of Inflammation. Hindawi Publishing Corporation. https://doi.org/10.1155/2014/493593
Mendeley helps you to discover research relevant for your work.